Christin Hendriyani Bonnu has completed his bachelor at the age of 22 years from Universitas Nusa Cendana and now studying at Universitas Gadjah Mada in Biotechnology department. This is the first time for her attending an international conference and she has no intenational publication before.
Abstract
The usual diagnostic method to diagnostic Prostate cancer is the PSA (prostate specific antigen) method. However this method is considered to be less effective because the interpretation of the value in cancer patients can be the same as in BPH (Benign Prostate Hypertrophy) patients or other prostate infections. One alternative diagnostic method that can be combined with this usual method to reach best result is finding the molecular signature of this cancer. The aim of this study is to determine microRNAs that can use as biomarkers of prostate cancer. The method used in this study is microRNA expression analysis in two prostate cancer tissue samples and two BPH tissue samples using Nanostring nCounter ®, validation by microarray database and molecular docking. The result shows that there are 7 miRNAs with p values ​​close to 1. There are hsa-mir-98-5p, hsa-let-7a-5p, hsa-mir-106b-5p, hsa-mir-1-3p which are upregulated and hsa-mir- 25-3p, hsa-mir-205-5p, hsa-mir-152-3p which are downregulated in prostate cancer. Microarray database analysis proves the dysregulated microRNAs in prostate cancer are hsa-mir-25-3p, hsa-mir-106b-5p, hsa-let-7a-5p and hsa-mir-98-5p. The docking result shows that hsa-mir-25-3p has stronger interaction with E2F1 than hsa-mir-106b-5p. The last analysis from Kaplen Meier also shows that all these miRNAs have influence on patient’s survival rate, although it is unsignificantly. Our findings revealed that all these miRNAs have potential to be novel biomarker for prostate cancer patients, especially hsa-mir-25-3p and hsa-mir-106b-5p.
